Last updated: July 23, 2026
Collagenex is a collagen-based product brand tied to tissue- and wound-care use. The competitive landscape is shaped primarily by (1) the FDA status of each specific Collagenex product/strength/formulation, (2) whether the product is protected by listed Orange Book patents (for small-molecule generics) versus unlisted device/biologic-like protections (for biologics and medical devices), and (3) the practical IP barriers created by sterilization, crosslinking/processing, and supply-chain controls rather than by a single “blocker” patent family.
No patent or FDA product listing level data is provided here to produce a complete, accurate patent-expiration, Paragraph IV, litigation, or exclusivity timeline for “Collagenex” as a brand name that can map to specific FDA NDCs, active ingredients, and legal status.
What is Collagenex and which FDA products define its competitive set?
Collagenex is a collagen-derived platform name used in wound care and related indications, typically positioned against collagen dressings, acellular dermal matrices, and other advanced wound care (AWC) categories. The competitive set is defined less by “Collagenex the brand” and more by the exact FDA-regulated product type for the specific Collagenex SKU being evaluated (drug vs device vs biologic; and if drug, whether it is an NDA with Orange Book listings).
How does Collagenex compete versus collagen dressings and AWC comparators?
Competitive substitutability usually clusters around:
- Collagen-derived dressings and wound-contact layers
- Acellular dermal matrices and xenograft/allograft-like products
- Other AWC classes (including hydrocolloids, foams, antimicrobial dressings), based on indication fit
What product attributes drive substitution risk?
Across AWC, buying decisions and formulary placement typically hinge on:
- Exudate handling and dressing adherence
- Handling and change frequency
- Evidence of healing endpoints in target populations
- Safety profile (infection, inflammatory response, allergy risk)
- Supply reliability and reimbursement coding
What patents protect Collagenex and how strong is the patent estate?
A credible patent estate assessment requires mapping each Collagenex product to:
- The FDA application(s) and its Orange Book listings (if drug)
- Associated process/purification/sterilization and formulation patents (method-of-manufacture, crosslinking, compositional ranges, device-like labeling claims if applicable)
- Any listed exclusivities tied to the referenced FDA application
How many patents cover Collagenex and what are the assignees?
This requires product-to-patent mapping by:
- Patent numbers listed in the FDA Orange Book (if applicable)
- Patent families covering manufacturing and processing steps used to create the collagen material
- Any method-of-use or indication patents tied to clinical claims
Which patent types dominate: formulation, method-of-use, or manufacturing process?
For collagen-based platforms, practical freedom-to-operate often turns on:
- Production method claims (extraction, purification, sterilization, reconstitution)
- Crosslinking or stabilization chemistry (if used)
- Preservation and packaging that preserves activity and reduces lot variability
When does Collagenex lose exclusivity and how do exclusivity blocks work?
For NDA-based drugs, exclusivity and patent expiry drive generic entry timing through:
- Orange Book patent expiration dates
- Statutory exclusivity (if applicable): new chemical entity (NCE), new clinical investigations, orphan drug, pediatric extensions
- Terminal disclaimers and patent term adjustments
For devices/biologics, exclusivity and “blockers” work differently, and Paragraph IV is not the mechanism.
What is the Orange Book status of Collagenex products?
A product must be identified with its FDA NDC and application to determine:
- Whether any patents are listed
- Which patents are listed as drug substance vs drug product vs method-of-use
- The expiration dates and listed exclusivity periods
What exclusivity timelines apply in practice?
Timing scenarios depend on whether Collagenex is:
- A drug with Orange Book listings (patent and exclusivity expiry governs)
- A device (marketing authorization frameworks govern, not Orange Book)
- A biologic (BLA exclusivity and reference product data control entry)
How do competitors challenge Collagenex with generic or biosimilar-like substitutes?
“Generic” in the small-molecule sense requires an ANDA to a listed drug. For collagen-based wound care, many competitive entries behave like:
- Device equivalents (510(k) or de novo style pathways, depending on product type)
- Substantially similar wound products with different materials or processing
- Biologic-like or tissue-derivative substitutes where “biosimilar” terminology does not map cleanly
Do Paragraph IV challenges exist for Collagenex?
Paragraph IV exists only for ANDAs against Orange Book-listed patents for approved drugs. Without NDC/application mapping and Orange Book data for Collagenex products, a Paragraph IV / Hatch-Waxman risk call cannot be stated.
What generic entry risks exist for Collagenex?
Where substitutes enter, they do so via:
- Regulatory pathway equivalency (device/biologic vs drug)
- Manufacturing reproducibility and sterilization controls
- Patent or trade secret barriers in collagen processing
What formulations and processing features are protected for Collagenex?
Collagen-based IP protection commonly covers:
- Composition constraints: collagen source, concentration ranges, and excipient systems
- Processing parameters: extraction conditions, purification steps, enzymatic treatments
- Sterilization method claims and validation processes
- Packaging and shelf-life stabilization claims
Which dosage forms and delivery systems matter competitively?
For wound care collagen products, delivery system attributes likely include:
- Sheet, sponge, membrane, gel, or powder formats
- Dressing configurations (single-layer vs layered)
- Support materials and matrix structure
- Reconstitution or application workflow
What patent litigation affects Collagenex and what settlement patterns exist?
IP enforcement in wound-care collagen categories typically involves:
- Injunction-seeking actions for alleged infringement of formulation or manufacturing method patents
- Settlement agreements that define design-around obligations and launch calendars
- Licensing deals tied to continued supply and field-of-use limits
What cases involve Collagenex and how far have they progressed?
This requires case-level data (docket numbers, court, parties, asserted patents, claim construction outcomes, and settlement dates) tied to specific Collagenex product families.
How does Collagenex compare with leading advanced wound care competitors?
A competitive comparison must be grounded in:
- Indication and patient population served
- Clinical endpoints and evidence (time-to-heal, granulation, infection rate, dressing change frequency)
- Coverage and reimbursement (HCPCS/CPT coding, payer policies)
- Real-world adoption (contracting patterns and hospital formulary placement)
Collagenex versus collagen dressings: what differentiates value?
Typical differentiation axes:
- Material quality and lot consistency
- Handling and durability
- Evidence strength in target wounds
- Safety profile and ease of use for clinicians
Collagenex versus acellular dermal matrices and other AWC
Differentiation typically shifts to:
- Matrix structural integrity and integration
- Exudate management and biofilm control
- Cost per treatment course, not cost per unit
What is Collagenex revenue exposure from patent and regulatory timelines?
Revenue exposure analysis requires:
- Which Collagenex products are proprietary and which are exposed to substitution
- Gross sales by product/SKU and market channel
- Patent expiry and exclusivity timelines by SKU
- Expected competitive launch timing for likely entrants
Without product-level sales and legal timeline mapping, a reliable revenue-at-risk profile cannot be produced.
Key Takeaways
- Collagenex competition is defined by the exact FDA-regulated product type and SKU attributes, not by brand name alone.
- Patent strength for collagen-based wound care often depends on manufacturing/process claims and the ability of competitors to design around those steps.
- Exclusivity and generic/biosimilar risk cannot be quantified without mapping each Collagenex product to its specific FDA application, Orange Book status (if drug), and patent expiry dates.
FAQs
- How do I identify which Collagenex SKU has Orange Book-listed patents?
- What is the most common IP barrier for collagen-based wound care products: formulation or manufacturing process?
- When competitors enter wound care collagen markets, do they typically use ANDA pathways or device pathways?
- What evidence endpoints drive formulary adoption for collagen wound dressings?
- How should an investor or licensor evaluate freedom-to-operate risk for collagen-based products?
References
- U.S. Food and Drug Administration (FDA). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Drugs@FDA database. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. 510(k) Premarket Notification Program. https://www.fda.gov/medical-devices/premarket-submissions/premarket-notification-510k
